$SRDX News

Last published 11mo ago

11mo agoSRDXSurmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire TodayBusiness WireSurmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its
1y agoSRDXSurmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCRBusiness WireSurmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court
1y agoSRDXSurmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia PresentationsBusiness WireAnalysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms
1y agoSRDXSurmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3Business WirePROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with
1y agoSRDXSurmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy PlatformBusiness WireAnalysis of 160 patients with acute, subacute, or chronic symptoms of thrombotic limb ischemia receiving thromboemboli removal treatment with the Pounce™ Thrombectomy Platform demonstrated high procedural success
1y agoSRDXSurmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28Business WirePROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Results of a sex-specific analysis of 160 patients with
1y agoSRDXSurmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial GuidanceBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and
1y agoSRDXSurmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8Business WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be
1y agoSRDXSurmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial GuidanceBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and
1y agoSRDXSurmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30Business WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be
1y agoSRDXSurmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated BalloonBusiness WireEuropean Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT�� Admiral™ DCB having 75% Higher Paclitaxel
1y agoSRDXSurmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral ArteriesBusiness WireWith the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the fully mechanical Pounce™ Thrombectomy Platform can now remove thrombi or emboli throughout
1y agoSRDXSurmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCRBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's
1y agoSRDXSurmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral ArteriesBusiness WireWith the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the Pounce™ Thrombectomy Platform can now rapidly remove acute or chronic clot throughout the
1y agoSRDXSurmodics Reports First Quarter of Fiscal Year 2025 Financial ResultsBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31,
2y agoSRDXSurmodics Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended
2y agoSRDXSurmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy SystemBusiness WireEarly subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal
2y agoSRDXSurmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in DiameterBusiness WireThe Pounce™ Thrombectomy Platform can now be used to remove clot from peripheral arteries as small as 2mm up to as large as 10 mm in diameter, broadening the platform's clinical utility and significantly
2y agoSRDXSurmodics Reports Third Quarter of Fiscal Year 2024 Financial ResultsBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third
2y agoFFNW HCP CALB SRDXKuehn Law Encourages, FFNW, HCP, CALB, and SRDX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoSRDXSurmodics Awarded Thrombectomy Products Agreement with Premier, Inc.Business WireAccess to Premier's healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of
2y agoAMBC SGRP SRCL SRDXKuehn Law Encourages AMBC, SGRP, SRDX, and SRCL Investors to Contact Law FirmGlobeNewswireSOUTHAMPTON, N.Y., June 05, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional
2y agoATRI BLBX MRO SRDXKuehn Law Encourages SRDX, MRO, ATRI, and BLBX Investors to Contact Law FirmGlobeNewswireNEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoSRDXSRDX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Surmodics to GTCRGlobeNewswireMONSEY, N.Y., May 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $43.00 per share in cash for which Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics") has
2y agoSRDXSurmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 MillionBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a
2y agoSRDXSurmodics, Inc. (SRDX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoSRDXSurmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceBusiness WireAnnounces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical
2y agoSRDXSurmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Business WireEarnings Conference Call and Webcast Will Begin at 7:00 am (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that
2y agoSRDXSurmodics to Participate in Upcoming Investor Conferences in March and AprilBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor
2y agoSRDXSurmodics, Inc (SRDX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoSRDXSurmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and
2y agoSRDXSurmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the KneeBusiness WireAddition of a low-profile device to the Surmodics Pounce™ thrombectomy platform allows for efficient clot removal in peripheral arteries ranging from 2 mm to 4 mm, such as those found below the knee Surmodics,
2y agoSRDXSurmodics to Host Virtual Annual Meeting of ShareholdersBusiness WireVirtual Meeting on February 8 at 4 p.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of
2y agoSRDXSurmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1Business WireEarnings Conference Call and Webcast Will Begin at 7:00 am (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that
2y agoABT SRDXSurmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH SymposiumBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by
2y agoSRDXSurmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposiumBusiness WireSundance™ Sirolimus Drug-Coated Balloon exhibits excellent safety profile Primary patency maintained at 24 months in 71.4% of per protocol analysis population Surmodics, Inc. (NASDAQ:SRDX), a leading provider
2y agoSRDXSurmodics to Participate in the Piper Sandler Healthcare Conference on November 28Business WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler
3y agoSRDXSurmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial GuidanceBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended
3y agoSRDXSurmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15Business Wire35-subject SWING Trial evaluates the safety, performance of Surmodics' Sundance™ Sirolimus Drug-Coated Balloon Updated safety and performance data for the SWING trial 24-month data will be shared Surmodics,
3y agoABT SRDXSurmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH SymposiumBusiness WireDr. Peter A. Schneider to share trial results during a Nov. 15 session Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today
3y agoSRDXSurmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device ApplicationsBusiness WireSurmodics, Inc. (NASDAQ:SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic
3y agoSRDXSurmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8Business WireEarnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced
3y agoANEB DLHC HBIO HOOK+15Sidoti Events, LLC's Virtual August Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place
3y agoSRDXSurmodics, Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
3y agoSRDXSurmodics to Participate in Upcoming Investor Conferences in AugustBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor
3y agoSRDXSurmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial GuidanceBusiness WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and
3y agoKRMD SRDXKORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial OfficerBusiness WireKORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and
3y agoSRDXSurmodics Receives FDA Approval for the SurVeil™ Drug-Coated BalloonBusiness WireSurmodics to receive $27 million milestone payment from Abbott Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the
3y agoSRDXSurmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy SystemBusiness WireAddition to Pounce™ thrombectomy platform with the low-profile (LP) model will allow for efficient clot removal in below-the-knee peripheral arteries (2 mm to 4 mm), expanding the addressable market for the
3y agoSRDXSurmodics to Participate in the Jefferies Healthcare Conference on June 8Business WireSurmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the Jefferies Healthcare